Article Sidebar

pdf
Date Published: 23/06/2025
Abstract Views: 127
Views pdf: 57
DOI: https://doi.org/10.51298/vmj.v551i1.14508
Issue
Vol. 551 No. 1 (2025)
Section
Các bài báo
How to Cite
Bùi Thị Thu, H., Quách Thị, D., & Vũ Hồng, T. (2025). PROGRESSION-FREE SURVIVAL AND SOME FACTORS AFFECTING IN METASTASIC GASTRIC CANCER TREATED TS-1 PLUS OXALIPLATIN REGIMEN. Vietnam Medical Journal, 551(1). https://doi.org/10.51298/vmj.v551i1.14508

PROGRESSION-FREE SURVIVAL AND SOME FACTORS AFFECTING IN METASTASIC GASTRIC CANCER TREATED TS-1 PLUS OXALIPLATIN REGIMEN

Hoài Bùi Thị Thu, Dung Quách Thị, Thăng Vũ Hồng

Main Article Content

Abstract

Aims: To evaluate the progression-free survival time and some factors affecting the progression-free survival time in patients with advanced gastric cancer treated with TS-1 regimen combined with oxaliplatin. Research subject: Advanced stage, no longer able to undergo radical surgery, received first-line chemotherapy with TS-1 regimen combined with Oxaliplatin at K hospital from January 2019 to August 2022. Research method: Descriptive study. Results: The average progression-free survival time was 6.95±3.89 months, and the median was 6.02 months. The progression-free survival time was longer in patients with metastases <=2 sites. No significant correlation was found between progression-free survival time and gender, age group, cell differentiation, general health index, and symptomatic surgery. Conclusion: TS-1 regimen combined with Oxaliplatin improves progression-free survival in patients with advanced gastric cancer and is related to the number of metastatic sites. 

Article Details

Keywords

TS-1, oxaliplatin, gastric cancer, metastasis

References

1. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
2. Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3): 215-221. doi:10.1016/S1470-2045(08)70035-4
3. Yamada Y, Higuchi K, Nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. Ann Oncol. 2015; 26(1): 141-148. doi:10.1093/annonc/ mdu472
4. Lee KW, Chung IJ, Ryu MH, et al. Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial). Gastric Cancer Off J Int Gastric Cancer Assoc Jpn Gastric Cancer Assoc. 2021;24(1):156-167. doi:10.1007/s10120-020-01101-4
5. Nguyễn Minh Phương. Đánh giá kết quả phác đồ TS1-Cisplatin trong điều trị bước một ung thư dạ dày giai đoạn muộn tại bệnh viện K. Thesis. ĐHY; 2020.